Fundraising FoxNanocan Therapeutics
National Harbor, US · Founded 2020 · Delaware corporation · 4 known investors
Find your way into Nanocan Therapeutics
Sign up to see every warm intro you have to Nanocan Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nanocan Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
DK
Dave KrasneExecutive
EC
Eric C. BroylesExecutive
JP
Jacques P. WalkerExecutive
Investors · 4
ACADEMY INVESTORlisted by ACADEMY INVESTORNew York
How we know: ACADEMY INVESTOR's portfolio page · Not right? Tell us
AIN Ventureslisted by AIN VenturesNew York · $500K – $1M
How we know: AIN Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Sand Hill Angelslisted by Sand Hill AngelsMenlo Park · $50K – $2M
How we know: sandhillangels.com · Not right? Tell us
Lifeforce CapitalreportedChevy Chase · $500K – $5M
How we know: press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$6.2M disclosed across 2 rounds · 2020–2022
▶$5.1MraisedFeb 2025 · 41 investors · BiotechnologyRule 506(b)
▶$5.1MraisedFeb 2025 · 41 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dave KrasneExecutive Officer
- Eric C. BroylesExecutive Officer, Director
- Jacques P. WalkerExecutive Officer, Director
- Offering amount
- $6.5M
- Amount sold
- $5.1M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$1.1MraisedAug 2020 · 6 investors · PharmaceuticalsRule 506(b)
▶$1.1MraisedAug 2020 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jacques WalkerExecutive Officer
- Eric BroylesExecutive Officer, Director
- Offering amount
- $1.4M
- Amount sold
- $1.1M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
NanobiotixNanobiotix develops physics-based nanotherapeutics for cancer treatment, applying nanotechnology to expand therapeutic options for oncology patients. The company builds on French scientific research and targets patients worldwide through disruptive treatment approaches.
Integrated Nanotherapeutics Inc.Integrated Nanotherapeutics develops lipid nanoparticle science and drug formulations for therapeutic applications. The company is led by scientists with over 100 years of collective expertise in preclinical research and drug development.
Transcode TherapeuticsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.
Jnana TherapeuticsJnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins. The platform uses proprietary reactive affinity probes and high-throughput screening to accelerate drug discovery across challenging target classes including transporters, transcription factors, and GPCRs.
Nanobots TherapeuticsNanobots Therapeutics develops the MotionTx platform to create nanobots that penetrate tissues and enhance drug accumulation in target cells for therapeutic applications. The company is a spin-off of ICREA and IBEC resulting from research by Prof. Samuel Sánchez.
Companies working in the same space as Nanocan Therapeutics.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $400K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $399.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- Who are Nanocan Therapeutics's investors?
- Nanocan Therapeutics's investors include ACADEMY INVESTOR, AIN Ventures, Sand Hill Angels, Lifeforce Capital.
- How much funding has Nanocan Therapeutics raised?
- Nanocan Therapeutics has disclosed $6.2M raised across 2 rounds.
- Where is Nanocan Therapeutics headquartered?
- Nanocan Therapeutics is headquartered in National Harbor, US.